表紙
市場調查報告書

急性呼吸窘迫症候群(ARDS):流行病學預測(至2030年)

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948131
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
急性呼吸窘迫症候群(ARDS):流行病學預測(至2030年) Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

急性呼吸窘迫症候群(ARDS)是重症患者中快速發展的疾病。 ARDS的原因分為兩類:對肺部的直接或間接損害。直接的肺損傷包括肺炎,抽吸和創傷,而間接的肺損傷包括胰腺炎症,嚴重感染(也稱為敗血症)和輸血,燒傷,藥物反應等。 ARDS的一些症狀是呼吸急促,咳嗽和發燒。在某些情況下,ARDS患者的心跳加快且呼吸加快。可能增加ARDS風險的一些風險因素包括肥胖,酗酒,化學療法和血液中蛋白質含量低。

本報告調查了七個主要全球市場(美國,德國,英國,意大利,法國,西班牙和日本)的急性呼吸窘迫綜合徵(ARDS)市場,市場概況,疾病背景/流行病學,我正在分析市場等。

第1章主要見解

第2章執行摘要

第3章SWOT分析

第4章急性呼吸窘迫症候群(ARDS):流行病學概述

  • 2017年流行病學在ARDS中的佔有率(%)
  • 2030年流行病學在ARDS中的佔有率(%)

第5章急性呼吸窘迫症候群(ARDS):疾病的背景和概述

  • 簡介
    • 急性肺損傷和急性呼吸窘迫症候群(ARDS)的共識定義
    • 柏林ARDS定義的發展
    • AECC定義和隨後的柏林急性呼吸窘迫症候群(ARDS)定義存在問題
  • 原因和危險因素
    • 急性呼吸窘迫症候群(ARDS)的危險因素
  • 急性呼吸窘迫症候群(ARDS)的病理生理學
    • ARDS炎症過程
    • 第一次傷害事件
    • 內皮損傷
    • ARDS中炎症和肺損傷的特定介質
    • ARDS呼吸生理的變化
    • 遺傳學
  • 急性呼吸窘迫症候群(ARDS)的階段
  • 呼吸機誘發的肺損傷(VILI)
  • VILI的主要決定因素
    • VILI呼吸機決定因素
    • VILI患者決定因素
  • 急性呼吸窘迫症候群(ARDS)的診斷
    • ARDS影像技術
    • ARDS的影像發現
    • 鑑別疾病

第6章許可設施

第7章流行病學和患者人數

  • 主要發現
  • 調查方法

第8章七個主要市場的流行病學分析

  • 七個主要市場的急性呼吸窘迫症候群(ARDS)患者總數
  • 七個主要市場中按嚴重程度劃分的急性呼吸窘迫症候群(ARDS)患者總數

第9章美國流行病學

  • 假設和依據
  • 總患者人數
  • 嚴重程度的總患者人數
  • 按危險因素劃分的總患者人數

第10章5個歐洲國家的流行病學

  • 德國流行病學
    • 假設和依據
    • 總患者人數
    • 嚴重程度的總患者人數
    • 按危險因素劃分的總患者人數
  • 法國流行病學
  • 意大利流行病學
  • 西班牙流行病學
  • 英國流行病學

第11章日本流行病學

  • 假設和依據
  • 總患者人數
  • 嚴重程度的總患者人數
  • 按危險因素劃分的總患者人數
目錄
Product Code: DIEI0002

DelveInsight's 'Acute Respiratory Distress Syndrome (ARDS)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome (ARDS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Acute Respiratory Distress Syndrome (ARDS) Understanding

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. The few symptoms of ARDS are shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risks factors that may escalate the risk for ARDS; this involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

Acute Respiratory Distress Syndrome (ARDS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of ARDS, Severity-specific Incidence of ARDS and Incidence of ARDS by Risk Factors scenario of Acute Respiratory Distress Syndrome (ARDS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Acute Respiratory Distress Syndrome (ARDS) Detailed Epidemiology Segmentation

  • In the 7MM, the total incident population of ARDS is estimated to be 799,872 in 2017.
  • Generally, the highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which sepsis was the primary risk factor for ARDS.
  • The estimates show a higher incidence of ARDS in the United States with 495,655 cases in 2017.

Scope of the Report:

  • The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute Respiratory Distress Syndrome (ARDS).
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Acute Respiratory Distress Syndrome (ARDS), Total Diagnosed and Treated Cases of Acute Respiratory Distress Syndrome (ARDS).

Report Highlights:

  • Eleven-Year Forecast of Acute Respiratory Distress Syndrome (ARDS)
  • 7MM Coverage
  • Total Incident Population of ARDS
  • Severity-specific Incidence of ARDS
  • Incidence of ARDS by Risk Factors
  • Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is estimated to increase at a CAGR of 1.07%
  • Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is projected to rise at a CAGR of 0.92%.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Acute Respiratory Distress Syndrome (ARDS)?
  • What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Respiratory Distress Syndrome (ARDS)?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)? 

Reasons to buy:

The Acute Respiratory Distress Syndrome (ARDS) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.
  • Quantify patient populations in the 7MM Acute Respiratory Distress Syndrome (ARDS) market to improve product design, pricing, and launch plans.
  • The Acute Respiratory Distress Syndrome (ARDS) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Acute Respiratory Distress Syndrome (ARDS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Acute Respiratory Distress Syndrome (ARDS): Epidemiology Overview at a Glance

  • 4.1 Total Epidemiology Share (%) Distribution of ARDS in 2017
  • 4.2 Total Epidemiology Share (%) Distribution of ARDS in 2030

5 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

  • 5.1 Introduction
    • 5.1.1 Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
    • 5.1.2 Development of Berlin Definition of ARDS
    • 5.1.3 Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress syndrome (ARDS)
  • 5.2 Causes and Risk Factors
    • 5.2.1 Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
  • 5.3 Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
    • 5.3.1 Inflammatory Processes in ARDS
    • 5.3.2 The initial event of injury
    • 5.3.3 Endothelial Damage
    • 5.3.4 Specific Mediators of Inflammation and Lung Damage in ARDS
    • 5.3.5 Altered Pulmonary Physiology in ARDS
    • 5.3.6 Genetics
  • 5.4 Stages of Acute Respiratory Distress Syndrome (ARDS)
  • 5.5 Ventilator-Induced Lung Injury (VILI)
  • 5.6 Major Determinants of VILI
    • 5.6.1 Ventilator determinants of VILI
    • 5.6.2 Patient determinants of VILI
  • 5.7 Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
    • 5.7.1 Imaging techniques in ARDS
    • 5.7.2 Imaging findings in ARDS
    • 5.7.3 Differential Diagnosis

6 Recognized Establishments

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Methodology

8 7MM Epidemiology Analysis

  • 8.1 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
  • 8.2 Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

9 United States Epidemiology

  • 9.1 Assumptions and Rationale
  • 9.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
  • 9.3 Severity-specific Incident Population of ARDS in the United States
  • 9.4 Incident Population of ARDS by Risk Factors in the United States

10 EU5 Epidemiology

  • 10.1 Germany Epidemiology
    • 10.1.1 Assumptions and Rationale
    • 10.1.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany
    • 10.1.3 Severity-specific Incidence of ARDS in Germany
    • 10.1.4 Incident Population of ARDS by Risk Factors in Germany
  • 10.2 France Epidemiology
    • 10.2.1 Assumptions and Rationale
    • 10.2.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), in France
    • 10.2.3 Severity-specific Incidence of ARDS in France
    • 10.2.4 Incident Population of ARDS by Risk Factors in France
  • 10.3 Italy Epidemiology
    • 10.3.1 Assumptions and Rationale
    • 10.3.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy
    • 10.3.3 Severity-specific Incidence of ARDS in Italy
    • 10.3.4 Incident Population of ARDS by Risk Factors in Italy
  • 10.4 Spain Epidemiology
    • 10.4.1 Assumptions and Rationale
    • 10.4.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain
    • 10.4.3 Severity-specific Incidence of ARDS in Spain
    • 10.4.4 Incident Population of ARDS by Risk Factors in Spain
  • 10.5 United Kingdom Epidemiology
    • 10.5.1 Assumptions and Rationale
    • 10.5.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom
    • 10.5.3 Severity-specific Incidence of ARDS in the United Kingdom
    • 10.5.4 Incident Population of ARDS by Risk Factors in the United Kingdom

11 Japan Epidemiology

  • 11.1 Assumptions and Rationale
  • 11.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), ARDS in Japan
  • 11.3 Severity-specific Incidence of ARDS in Japan
  • 11.4 Incident Population of ARDS by Risk Factors in Japan

List of Tables

  • Table 1: Definition of Acute Respiratory Distress Syndrome (ARDS)
  • Table 2: American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
  • Table 3: Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
  • Table 4: Factors That Distinguish ARDS, CHF, and Pneumonia
  • Table 5: Total Incident Population of ARDS in the 7MM (2017-2030)
  • Table 6: Severity-specific Incident Population of ARDS in the 7MM (2017-2030)
  • Table 7: Total Incident Population of ARDS in the US (2017-2030)
  • Table 8: Severity-specific Incident Population of ARDS in the US (2017-2030)
  • Table 9: Incidence of ARDS by Risk Factors in the US (2017-2030)
  • Table 10: Total Incident Population of ARDS in Germany (2017-2030)
  • Table 11: Severity-specific Incident Population of ARDS in Germany (2017-2030)
  • Table 12: Incidence of ARDS by Risk Factors in Germany (2017-2030)
  • Table 13: Total Incident Population of ARDS in France (2017-2030)
  • Table 14: Severity-specific Incident Population of ARDS in France (2017-2030)
  • Table 15: Incidence of ARDS by Risk Factors in France (2017-2030)
  • Table 16: Total Incident Population of ARDS in Italy (2017-2030)
  • Table 17: Severity-specific Incident Population of ARDS in Italy (2017-2030)
  • Table 18: Incidence of ARDS by Risk Factors in Italy (2017-2030)
  • Table 19: Total Incident Population of ARDS in Spain (2017-2030)
  • Table 20: Severity-specific Incident Population of ARDS in Spain (2017-2030)
  • Table 21: Incidence of ARDS by Risk Factors in Spain (2017-2030)
  • Table 22: Total Incident Population of ARDS in the UK (2017-2030)
  • Table 23: Severity-specific Incident Population of ARDS in the UK (2017-2030)
  • Table 24: Incidence of ARDS by Risk Factors in the UK (2017-2030)
  • Table 25: Total Incident Population of ARDS in Japan (2017-2030)
  • Table 26: Severity-specific Incident Population of ARDS in Japan(2017-2030)
  • Table 27: Incidence of ARDS by Risk Factors in Japan (2017-2030)

List of Figures

  • Figure 1: Acute Respiratory Distress Syndrome (ARDS) SWOT Analysis
  • Figure 2: Common Symptoms of Acute Respiratory Distress Syndrome (ARDS)
  • Figure 3: Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
  • Figure 4: Pathophysiology of ABPA
  • Figure 5: Proposed Algorithm for the Diagnosis of CPA
  • Figure 6: Algorithm for the Diagnosis of ABPA in Asthma
  • Figure 7: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in the 7MM Countries (2017-2030)
  • Figure 8: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in the 7MM Countries (2017-2030)
  • Figure 9: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in the United States (2017-2030)
  • Figure 10: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in the United States (2017-2030)
  • Figure 11: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Germany (2017-2030)
  • Figure 12: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Germany (2017-2030)
  • Figure 13: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in France (2017-2030)
  • Figure 14: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in France (2017-2030)
  • Figure 15: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Italy (2017-2030)
  • Figure 16: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Italy (2017-2030)
  • Figure 17: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Spain (2017-2030)
  • Figure 18: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Spain (2017-2030)
  • Figure 19: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in the UK (2017-2030)
  • Figure 20: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by type in the UK (2017-2030)
  • Figure 21: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Japan (2017-2030)
  • Figure 22: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Japan (2017-2030)